BAR502

BAR502 is a synthetic small molecule and bile acid analogue that acts as a dual agonist of the Farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5). It is being developed primarily for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), nonalcoholic steatohepatitis (NASH), and cholestasis. Preclinical studies have shown that BAR502 reduces hepatic steatosis and fibrosis in rodent models, with additional beneficial effects on insulin sensitivity and inflammation. The drug is currently in early clinical development, including Phase 1 safety studies in healthy volunteers and Phase 2 trials for MASLD. Research has also explored its use in combination therapies to enhance efficacy against liver diseases[2][5][6].

Other names

dual farnesoid X receptor /TGR5 agonist